Edgewise Therapeutics (EWTX) announced the appointment of Michael Nofi, as CFO, effective November 10. Nofi joins Edgewise after serving as Chief Accounting Officer at SpringWorks Therapeutics. Nofi will succeed Edgewise CFO, Michael Carruthers, who is retiring.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Reports Q3 2025 Financial Results
- Edgewise Therapeutics reports Q3 EPS (39c), consensus (40c)
- Edgewise Therapeutics price target raised to $33 from $30 at JPMorgan
- Edgewise Therapeutics Advances with Phase 1 Study of EDG-15400
- Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study